Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model.

Additionally, after 10 days, idelalisib-treated cells showed a trend toward decreased mitochondrial membrane potential, associated with more quiescent metabolic phenotype, increased SRC and maximum OCR:ECAR ratio, and a significant reduction in glycolytic capacity, aligning with memory T-cell characteristics 44 ( Figure 6 A-B; supplemental Figure 5 E).

also in 53,322 other papers